Marc Ferrante
Experienced in Lump in the Abdomen

Dr. Marc Ferrante

Radiology
Advanced Radiology Mri Centers Lp
1055 Post Rd, 
Fairfield, CT 
 (1667.7 mi)
Clinical Trials:Currently Recruiting for 1 Trial
14 Years of Experience
Experienced in Lump in the Abdomen
Advanced Radiology Mri Centers Lp
1055 Post Rd, 
Fairfield, CT 
 (1667.7 mi)
OverviewInsuranceLocationsClinical Research

Overview

Marc Ferrante is a Radiologist in Fairfield, Connecticut. Dr. Ferrante has been practicing medicine for over 14 years and is rated as an Experienced provider by MediFind in the treatment of Lump in the Abdomen. His top areas of expertise are Colonic Malakoplakia, ALK-Positive Non-Small Cell Lung Cancer, Gas Bloat Syndrome, Endoscopy, and Colonoscopy.

His clinical research consists of co-authoring 321 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2011
Specialties
Radiology
Licenses
Diagnostic Radiology in CT
Hospital Affiliations
St Vincent's Medical Center
Bridgeport Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

ADVANCED RADIOLOGY MRI CENTERS LP
1055 Post Rd, Fairfield, CT 06824
Other Locations
ADVANCED RADIOLOGY MRI CENTERS LP
60 Danbury Rd, Suite 101, Wilton, CT 06897
ADVANCED RADIOLOGY CONSULTANTS LLC
4 Corporate Dr, Suite 182, Shelton, CT 06484
ADVANCED RADIOLOGY CONSULTANTS LLC
15 Corporate Dr, Trumbull, CT 06611
BRIDGEPORT RADIOLOGICAL ASSOCIATES LLC
267 Grant St, Bridgeport, CT 06610
ADVANCED RADIOLOGY MRI CENTERS LP
1259 E Main St, Stamford, CT 06902
ADVANCED RADIOLOGY MRI CENTERS LP
2876 Main St, Stratford, CT 06614
ADVANCED RADIOLOGY MRI CENTERS LP
30 Danbury Rd, Wilton, CT 06897
BRIDGEPORT RADIOLOGICAL ASSOCIATES LLC
2800 Main St, Bridgeport, CT 06606
ADVANCED RADIOLOGY MRI CENTERS LP
297 Boston Post Rd, Orange, CT 06477

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Recruiting
Publish Date: February 25, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2025
Intervention Type: Biological
Study Drug: Vedolizumab
Study Phase: Phase 4
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Other
Study Drug: Cx601
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
ENTYVIO® Real-World Outcomes in Bio-naïve Crohn's Disease Patients in Belgium, Australia, and Switzerland: An EVOLVE Observational Expansion Study
ENTYVIO® Real-World Outcomes in Bio-naïve Crohn's Disease Patients in Belgium, Australia, and Switzerland: An EVOLVE Observational Expansion Study
Enrollment Status: Completed
Publish Date: October 21, 2022
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: April 27, 2022
Intervention Type: Drug
Study Drug: GSK2831781
Study Phase: Phase 2
Multicentric, Double-blind, Placebo Controlled Clinical Trial With 5-hydroxytryptophan (5-HTP) in Patients With Inflammatory Bowel Disease in Clinical and Biologic Remission: Effect on Fatigue Scores
Multicentric, Double-blind, Placebo Controlled Clinical Trial With 5-hydroxytryptophan (5-HTP) in Patients With Inflammatory Bowel Disease in Clinical and Biologic Remission: Effect on Fatigue Scores
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Drug: 5-HTP
Study Phase: Phase 2
View 8 Less Clinical Trials

320 Total Publications

Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies.
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies.
Journal: Journal of Crohn's & colitis
Published: January 13, 2025
Similar Doctors
Elite in Lump in the Abdomen
Dr. Henry C. Kwok
Radiology
Elite in Lump in the Abdomen
Dr. Henry C. Kwok
Radiology
1233 York Ave Apt 8j, 
New York, NY 
 (45.5 mi)
917-455-2730
Languages Spoken:
English

Henry Kwok is a Radiologist in New York, New York. Dr. Kwok and is rated as an Elite provider by MediFind in the treatment of Lump in the Abdomen. His top area of expertise is Lump in the Abdomen.

Distinguished in Lump in the Abdomen
Dr. Sinchun Hwang
Radiology
Distinguished in Lump in the Abdomen
Dr. Sinchun Hwang
Radiology

Mskcc Radiology Group

1275 York Ave, 
New York, NY 
 (45.2 mi)
212-639-2000
Experience:
26+ years
Languages Spoken:
English

Sinchun Hwang is a Radiologist in New York, New York. Dr. Hwang has been practicing medicine for over 26 years and is rated as a Distinguished provider by MediFind in the treatment of Lump in the Abdomen. Her top areas of expertise are Lump in the Abdomen, Liposarcoma, Undifferentiated Pleomorphic Sarcoma, and Myxoid Liposarcoma.

Advanced in Lump in the Abdomen
Dr. Robert H. Siegelbaum
Radiology | Interventional Radiology
Advanced in Lump in the Abdomen
Dr. Robert H. Siegelbaum
Radiology | Interventional Radiology

Mskcc Radiology Group

650 Commack Rd, 
Commack, NY 
 (23.3 mi)
631-623-4300
Languages Spoken:
English

Robert Siegelbaum is a Radiologist and an Interventional Radiologist in Commack, New York. Dr. Siegelbaum and is rated as a Distinguished provider by MediFind in the treatment of Lump in the Abdomen. His top areas of expertise are Lymphoid Hyperplasia, Lymphofollicular Hyperplasia, Pancreatic Cancer, Familial Pancreatic Cancer, and Liver Embolization.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile